1. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Issue 10249 (15th August 2020) Authors: Zhu, Feng-Cai; Guan, Xu-Hua; Li, Yu-Hua; Huang, Jian-Ying; Jiang, Tao; Hou, Li-Hua; Li, Jing-Xin; Yang, Bei-Fang; Wang, Ling; Wang, Wen-Juan; Wu, Shi-Po; Wang, Zhao; Wu, Xiao-Hong; Xu, Jun-Jie; Zhang, Zhe; Jia, Si-Yue; Wang, Bu-Sen; Hu, Yi; Liu, Jing-Jing; Zhang, Jun Journal: Lancet Issue: Volume 396:Issue 10249(2020) Page Start: 479 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Issue 8 (August 2022) Authors: Li, Jing-Xin; Wu, Shi-Po; Guo, Xi-Ling; Tang, Rong; Huang, Bao-Ying; Chen, Xiao-Qin; Chen, Yin; Hou, Li-Hua; Liu, Jing-Xian; Zhong, Jin; Pan, Hong-Xing; Shi, Feng-Juan; Xu, Xiao-Yu; Li, Zhuo-Pei; Zhang, Xiao-Yin; Cui, Lun-Biao; Tan, Wen-Jie; Chen, Wei; Zhu, Feng-Cai; Li, Jing-Xin Journal: Lancet Issue: Volume 10:Issue 8(2022) Page Start: 739 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Issue 10240 (13th June 2020) Authors: Zhu, Feng-Cai; Li, Yu-Hua; Guan, Xu-Hua; Hou, Li-Hua; Wang, Wen-Juan; Li, Jing-Xin; Wu, Shi-Po; Wang, Bu-Sen; Wang, Zhao; Wang, Lei; Jia, Si-Yue; Jiang, Hu-Dachuan; Wang, Ling; Jiang, Tao; Hu, Yi; Gou, Jin-Bo; Xu, Sha-Bei; Xu, Jun-Jie; Wang, Xue-Wen; Wang, Wei Journal: Lancet Issue: Volume 395:Issue 10240(2020) Page Start: 1845 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗